IL2 and neoplasm: We have previously described the design and evaluation of an IL-2 mutein with a reduced binding capacity to the alpha chain of the IL-2R, named ‘no-alpha mutein’; mutein shows a higher anti-metastatic effect and less toxicity than wtIL-2, opening the opportunity to a better IL-2-based tumor therapy (16).